相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review
Colum Downey
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2016)
Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents
Jordan Axelrad et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis
Silvia Minozzi et al.
EXPERT OPINION ON DRUG SAFETY (2016)
Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Louise K. Mercer et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
R. Landewe et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study
Tsutomu Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double- blind randomised placebo- controlled study (RAPID-PsA)
P. J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial
Feng Huang et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Análise sistemática da influência do antifator de necrose tumoral [anti-TNF] sobre as taxas de infecção em pacientes com artrite reumatoide
Leslie Goh et al.
Revista Brasileira De Reumatologia (2014)
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study
Jacqueline Detert et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register
James B. Galloway et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX
Ernest Choy et al.
RHEUMATOLOGY (2012)
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
James B. Galloway et al.
RHEUMATOLOGY (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
R. Fleischmann et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events
J. P. Leombruno et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Randomized, Double-blind, Placebo-controlled, Comparative Study of Human Anti-TNF Antibody Adalimumab in Combination with Methotrexate and Methotrexate Alone in Taiwanese Patients with Active Rheumatoid Arthritis
Der-Yuan Chen et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2009)
Golimumab inpatients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
Josef S. Smolen et al.
LANCET (2009)
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
Jasvinder A. Singh et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2009)
Effect of the Early Use of the Anti-Tumor Necrosis Factor Adalimumab on the Prevention of Job Loss in Patients With Early Rheumatoid Arthritis
Victoria Bejarano et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety
Alberto Alonso-Ruiz et al.
BMC MUSCULOSKELETAL DISORDERS (2008)
Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study
Nobuyuki Miyasaka
MODERN RHEUMATOLOGY (2008)
The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis
Christopher J. Edwards et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis
S. Bernatsky et al.
RHEUMATOLOGY (2007)
All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists
Loreto Carmona et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Anti-tumor necrosis factor a therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis
Sebastian Schneeweiss et al.
ARTHRITIS AND RHEUMATISM (2007)
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists
Jeffrey R. Curtis et al.
ARTHRITIS AND RHEUMATISM (2007)
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy - Results from the British Society for Rheumatology Biologics Register
W. G. Dixon et al.
ARTHRITIS AND RHEUMATISM (2006)
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
T Bongartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia - Associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy
F Wolfe et al.
ARTHRITIS AND RHEUMATISM (2006)
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
FC Breedveld et al.
ARTHRITIS AND RHEUMATISM (2006)
Infections in patients with rheumatoid arthritis treated with biologic agents
J Listing et al.
ARTHRITIS AND RHEUMATISM (2005)
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study) - A randomized, controlled trial
YPM Goekoop-Ruiterman et al.
ARTHRITIS AND RHEUMATISM (2005)
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate
RN Maini et al.
ARTHRITIS AND RHEUMATISM (2004)
The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients
JF Colombel et al.
GASTROENTEROLOGY (2004)
Granulomatous infectious diseases associated with tumor necrosis factor antagonists
RS Wallis et al.
CLINICAL INFECTIOUS DISEASES (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy
S Kroesen et al.
RHEUMATOLOGY (2003)
Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
ME Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2003)
Frequency of infection in patients with rheumatoid arthritis compared with controls - A population-based study
MF Doran et al.
ARTHRITIS AND RHEUMATISM (2002)
Anti-TNF agents for rheumatoid arthritis
HE Seymour et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent
J Keane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
